(Arthritis, general) articles in PubMed
- Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials. [Journal Article]
- Drug Des Devel Ther 2016; 10:2771-2777DD
- T-helper 17 (Th17) pathway plays an important and distinct role in autoimmunity and inflammation. A growing body of evidence demonstrates that interleukin-17 (IL-17) is also synthesized in inflammato...
T-helper 17 (Th17) pathway plays an important and distinct role in autoimmunity and inflammation. A growing body of evidence demonstrates that interleukin-17 (IL-17) is also synthesized in inflammatory arthritis tissues and exerts potent proinflammatory and joint-destructive activities. Clinical studies have been performed to evaluate the therapeutic efficacy of antibodies blocking the IL-17 signaling pathway in patients with rheumatoid arthritis (RA). In this study, we performed a meta-analysis to systematically evaluate the clinical effects of IL-17 antibodies in RA patients. By searching PubMed, five randomized, placebo-controlled randomized controlled clinical trials that tested three antibodies against IL-17A (LY2439821 and secukinumab/AIN457) and the IL-17A receptor (brodalumab) were identified. The primary outcomes that were analyzed include American College of Rheumatology (ACR) Improvement Criteria and Disease Activity Score in 28 joints (DAS28). Meanwhile, the safety and adverse effects were also systematically analyzed. The results of the meta-analysis demonstrated that IL-17 antibody is effective in ameliorating the RA symptoms. Specifically, IL-17-blocking antibody significantly reduced ACR20 and ACR50. It also dramatically reduced DAS28, an index that measures tenderness and swelling severity of joints. The side effects of and intolerance to the antibody treatment were higher than those in the placebo control. The analysis result provides evidence-based information for clinical use of these agents in the treatment of inflammatory arthritis.
- Pharmacological studies on the anti-inflammatory and immunomodulatory role of pentoxifylline and its interaction with nitric oxide (NO) in experimental arthritis in rats. [Journal Article]
- Inflammopharmacology 2016 Sep 26I
- CONCLUSIONS: These results are suggestive of protective effects of pentoxifylline and its potentiation in combination with low dose of NO modulators. These results may provide new pharmacological therapy for management of rheumatoid arthritis (RA).
- Glucosamine exposure reduces proteoglycan synthesis in primary human endothelial cells in vitro. [Journal Article]
- Food Nutr Res 2016; 60:32615FN
- CONCLUSIONS: Exposure of endothelial cells to GlcN leads to a general decrease in (35)S-PG synthesis. These results suggest that exposure to high levels of GlcN can lead to decreased matrix synthesis, contrary to what has been claimed by supporters of such supplements.
- Cross-sectional association between muscle strength and self-reported physical function in 195 hip osteoarthritis patients. [Journal Article]
- Semin Arthritis Rheum 2016 Aug 16SA
- CONCLUSIONS: Greater isometric strength of specific hip and thigh muscle groups may be associated with better self-reported physical function in men and women. In people with mild physical dysfunction, an estimate of MCII in physical function may be associated with attainable increases in strength. However, in patients with more severe dysfunction, greater and perhaps unattainable strength increases may be associated with an estimate of MCII in physical function. Longitudinal studies are required to validate these observations.
- Rheumatology training experience across Europe: analysis of core competences. [Journal Article]
- Arthritis Res Ther 2016; 18(1):213AR
- CONCLUSIONS: Even though self-reported ability is generally high, there are significant differences amongst European countries, including differences in the learning structure and assessment of competences. This suggests that educational outcomes may also differ. Efforts to promote European harmonization in rheumatology training should be encouraged and supported.
- Macrophages mediated diagnosis of rheumatoid arthritis using fibrin based magnetic nanoparticles as MRI contrast agents. [Journal Article]
- Biochim Biophys Acta 2016 Sep 20BB
- CONCLUSIONS: The animal experiment results indicate that FA-MFNPs can be used as a specific MRI contrast agent in identifying phagocytic active macrophages in the synovial joints.Blood is the precursor source for synthesising the fibrin-based iron oxide (magnetic) nanoparticles (MFNPs) with diameters between 12 and 15nm. It has excellent superparamagnetic behaviour, biocompatibility, osteogenic potency, hemocompatibility, and biodegradable properties. MFNPs-based nanocomposites might be a promising contrast agent for bioimaging.
- Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. [Journal Article]
- Mod Rheumatol 2016 Sep 23; :1-5MR
- CONCLUSIONS: Neither denosumab nor bisphosphonates could suppress inflammation or RA disease activity, but denosumab significantly suppressed a marker of bone metabolism in Japanese RA patients never previously treated for osteoporosis.
- Hip structure analysis by DXA of teriparatide treatment: A 24-month follow-up clinical study. [Journal Article]
- J Orthop 2016; 13(4):414-8JO
- CONCLUSIONS: Based on the HSA results obtained with DXA, TPTD was effective for hip structures.
- Standard dose versus low dose of azathioprine in the treatment of Crohn's Disease: a prospective randomized study. [Journal Article]
- J Dig Dis 2016 Sep 21JD
- CONCLUSIONS: 2 mg/kg/d of AZA is more appropriate than 1 mg/kg/d for Chinese CD patients with a high efficacy rate, a low recurrence rate and no ascent in adverse events.
New Search Next
- Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. [Journal Article]
- RMD Open 2016; 2(2):e000270RO
- CONCLUSIONS: Intensive corticosteroid treatment in early RA improves physical but not mental health, relative to placebo. In established RA, cDMARDs and TNFi provide similar improvements in HRQoL. As remission optimises but fails to normalise HRQoL, a focus on treatment strategies targeting HRQoL is required.